2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
This guideline cites 3 of the 199 landmark trials in our Cardiology register.
- Issued by
- ACC/
AHA - Year
- 2024
- Source
- Ommen SR, Ho CY, et al. Circulation. 2024;149(23):e1239–e1311. (Reaffirmed as current, May 2025.)doi 10.1161/CIR.0000000000001250
The dedicated US HCM guideline — the ESC covers HCM inside its 2023 cardiomyopathy document — and it was reaffirmed as current in May 2025. It gives cardiac myosin inhibitors a formal place in symptomatic obstructive HCM on the strength of EXPLORER-HCM and VALOR-HCM, and it loosens the old blanket restriction on vigorous exercise, which now becomes a shared decision rather than a prohibition. The most persistent transatlantic difference is sudden-death risk stratification: the ACC/AHA works from a set of individual major risk markers plus imaging (apical aneurysm, extensive late gadolinium enhancement), while the ESC calculates the HCM Risk-SCD five-year probability — the two approaches select overlapping but not identical patients for an ICD. The register's HCM trials are grouped below.
Cardiac myosin inhibitors: obstructive HCM2
- 2022VALOR-HCMCardiology · HF · myosin inhibitorIn 112 patients with obstructive HCM referred for septal reduction therapy, mavacamten reduced the need to proceed with or remain eligible for septal reduction therapy compared with placebo.17.9% vs 76.8%Read →
- 2020EXPLORER-HCMCardiology · HF · myosin inhibitorIn 251 patients with symptomatic obstructive HCM (NYHA II-III, LVOT gradient ≥50 mmHg), mavacamten improved the composite of peak VO2 and NYHA functional class compared with placebo.37% vs 17%Read →
Exercise & physical activity1
- 2017RESET-HCMCardiology · HF · Exercise in cardiomyopathyIn 136 adults with hypertrophic cardiomyopathy, 16 weeks of moderate-intensity aerobic exercise training produced a small increase in peak oxygen consumption, with no ventricular arrhythmias, compared with usual activity.Read →
Published since the guideline1
- 2024SEQUOIA-HCMCardiology · HF · myosin inhibitorIn 282 patients with symptomatic obstructive HCM, aficamten improved peak oxygen uptake on exercise testing compared with placebo.Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2020MAVERICK-HCM
Mavacamten dose-finding in non-obstructive HCM.
- 2023LIVE-HCM
Vigorous exercise was not associated with excess events — the basis for relaxing activity restrictions.
- 2023EXPLORER-LTE
Long-term extension of EXPLORER-HCM (mavacamten).
- 2018SHaRe Registry
The international HCM outcomes registry behind much of the natural-history data.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.